Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Opening Speaker: Tae Hoon Ahn |
The Importance of Earlier and Lower LDL-C Reduction in ASCVD Patients Lecturer: Byeong-Keuk Kim |
PROFICIO : Advanced Lipid Management with Evolocumab Lecturer: Sung Eun Kim |
Discussion |
Closing Speaker: Bum-Kee Hong |
The Paradigm Shift in the Updated Lipid Guidelines : A Focus on Very High-Risk Patients Lecturer: Chan Joo Lee |
FOURIER Study and Its Implication : A Focus on PAD Lecturer: Young-Guk Ko |